Literature DB >> 35644190

[Early risk factors for death in neonates with persistent pulmonary hypertension of the newborn treated with inhaled nitric oxide].

Ai-Min Qian1, Wen Zhu1, Yang Yang1, Ke-Yu Lu1, Jia-Li Wang1, Xu Chen1, Chu-Chu Guo1, Ya-Dong Lu1, Hui Rong1, Rui Chneg1.   

Abstract

OBJECTIVES: To evaluate the early risk factors for death in neonates with persistent pulmonary hypertension of the newborn (PPHN) treated with inhaled nitric oxide (iNO).
METHODS: A retrospective analysis was performed on 105 infants with PPHN (gestational age ≥34 weeks and age <7 days on admission) who received iNO treatment in the Department of Neonatology, Children's Hospital of Nanjing Medical University, from July 2017 to March 2021. Related general information and clinical data were collected. According to the clinical outcome at discharge, the infants were divided into a survival group with 79 infants and a death group with 26 infants. Univariate and multivariate Cox regression analyses were used to evaluate the risk factors for death in infants with PPHN treated with iNO. The receiver operating characteristic (ROC) curve was used to calculate the cut-off values of the factors in predicting the death risk.
RESULTS: A total of 105 infants with PPHN treated with iNO were included, among whom 26 died (26/105, 24.8%). The multivariate Cox regression analysis showed that no early response to iNO (HR=8.500, 95%CI: 3.024-23.887, P<0.001), 1-minute Apgar score ≤3 points (HR=10.094, 95%CI: 2.577-39.534, P=0.001), a low value of minimum PaO2/FiO2 within 12 hours after admission (HR=0.067, 95%CI: 0.009-0.481, P=0.007), and a low value of minimum pH within 12 hours after admission (HR=0.049, 95%CI: 0.004-0.545, P=0.014) were independent risk factors for death. The ROC curve analysis showed that the lowest PaO2/FiO2 value within 12 hours after admission had an area under the ROC curve of 0.783 in predicting death risk, with a sensitivity of 84.6% and a specificity of 73.4% at the cut-off value of 50, and the lowest pH value within 12 hours after admission had an area under the ROC curve of 0.746, with a sensitivity of 76.9% and a specificity of 65.8% at the cut-off value of 7.2.
CONCLUSIONS: Infants with PPHN requiring iNO treatment tend to have a high mortality rate. No early response to iNO, 1-minute Apgar score ≤3 points, the lowest PaO2/FiO2 value <50 within 12 hours after admission, and the lowest pH value <7.2 within 12 hours after admission are the early risk factors for death in such infants. Monitoring and evaluation of the above indicators will help to identify high-risk infants in the early stage.

Entities:  

Keywords:  Neonate; Nitric oxide; Persistent pulmonary hypertension; Risk factor

Mesh:

Substances:

Year:  2022        PMID: 35644190      PMCID: PMC9154377          DOI: 10.7499/j.issn.1008-8830.2111191

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  25 in total

1.  Inhaled nitric oxide inhibits NOS activity in lambs: potential mechanism for rebound pulmonary hypertension.

Authors:  S M Black; R S Heidersbach; D M McMullan; J M Bekker; M J Johengen; J R Fineman
Journal:  Am J Physiol       Date:  1999-11

2.  Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes.

Authors:  M C Walsh-Sukys; J E Tyson; L L Wright; C R Bauer; S B Korones; D K Stevenson; J Verter; B J Stoll; J A Lemons; L A Papile; S Shankaran; E F Donovan; W Oh; R A Ehrenkranz; A A Fanaroff
Journal:  Pediatrics       Date:  2000-01       Impact factor: 7.124

3.  Clinical and echocardiography predictors of response to inhaled nitric oxide in hypoxemic term and near-term neonates.

Authors:  Adrianne R Bischoff; Regan E Giesinger; Elaine Neary; Dany E Weisz; Jaques Belik; Patrick J McNamara
Journal:  Pediatr Pulmonol       Date:  2021-01-12

4.  Pulse oximetry vs. PaO2 metrics in mechanically ventilated children: Berlin definition of ARDS and mortality risk.

Authors:  Robinder G Khemani; Sarah Rubin; Sanjay Belani; Dennis Leung; Simon Erickson; Lincoln S Smith; Jerry J Zimmerman; Christopher J L Newth
Journal:  Intensive Care Med       Date:  2014-09-18       Impact factor: 17.440

5.  Clinical characteristics and factors associated with term and late preterm infants that do not respond to inhaled nitric oxide (iNO).

Authors:  Alexandra Almanzar Morel; Evan Shreck; Pradeep V Mally; Yang Kim; Sean M Bailey; Elena V Wachtel
Journal:  J Perinat Med       Date:  2016-08-01       Impact factor: 1.901

Review 6.  Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn.

Authors:  Mei-Yin Lai; Shih-Ming Chu; Satyan Lakshminrusimha; Hung-Chih Lin
Journal:  Pediatr Neonatol       Date:  2017-08-10       Impact factor: 2.083

7.  Oxygen saturation index and severity of hypoxic respiratory failure.

Authors:  Munmun Rawat; Praveen K Chandrasekharan; Ashley Williams; Sylvia Gugino; Carmon Koenigsknecht; Daniel Swartz; Chang Xing Ma; Bobby Mathew; Jayasree Nair; Satyan Lakshminrusimha
Journal:  Neonatology       Date:  2015       Impact factor: 4.035

8.  Factors affecting the response to inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn infants.

Authors:  Soo Jung Hwang; Kye Hyang Lee; Jong Hee Hwang; Chang Won Choi; Jae Won Shim; Yun Sil Chang; Won Soon Park
Journal:  Yonsei Med J       Date:  2004-02-29       Impact factor: 2.759

Review 9.  Inhaled nitric oxide therapy in neonates and children: reaching a European consensus.

Authors:  Duncan J Macrae; David Field; Jean-Christophe Mercier; Jens Møller; Tom Stiris; Paolo Biban; Paul Cornick; Allan Goldman; Sylvia Göthberg; Lars E Gustafsson; Jürg Hammer; Per-Arne Lönnqvist; Manuel Sanchez-Luna; Gunnar Sedin; Nim Subhedar
Journal:  Intensive Care Med       Date:  2004-01-13       Impact factor: 17.440

Review 10.  The fetal circulation, pathophysiology of hypoxemic respiratory failure and pulmonary hypertension in neonates, and the role of oxygen therapy.

Authors:  S Lakshminrusimha; O D Saugstad
Journal:  J Perinatol       Date:  2016-06       Impact factor: 2.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.